| Autor: |
Shevelev VI; Kuban State Medical University, Krasnodar, Russia., Kanorsky SG; Kuban State Medical University, Krasnodar, Russia. |
| Jazyk: |
ruština |
| Zdroj: |
Kardiologiia [Kardiologiia] 2015 Oct; Vol. 55 (10), pp. 58-63. |
| DOI: |
10.18565/cardio.2015.10.58-63 |
| Abstrakt: |
We compared efficacy and safety of warfarin with those of direct thrombin inhibitor dabigatran, factor Xa inhibitors rivaroxaban and apixaban used for stroke prevention in 280 patients aged 65-80 years with non-valvular atrial fibrillation. Treatment for two years with dabigatran (110 mg twice daily), apixaban (5 mg twice daily) or rivaroxaban (20 mg/day) prevented strokes no less successfully than warfarin, but more rarely caused severe intracranial hemorrhages. When selecting antithrombotic therapy in geriatric patients with non-valvular AF new oral anticoagulants may be regarded as an acceptable alternative to warfarin. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
